



11 JUL 2006

LAHIVE & COCKFIELD, LLP
28 State Street
Boston, MA 02109

In re Application of :
HIMAWAN *et al* :
U.S. Application No.: 10/551,525 :
PCT No.: PCT/US2004/009622 :
Int. Filing Date: 29 March 2004 :
Priority Date: 28 March 2003 :
Attorney's Docket No.: ELI-037US :
For: IMMUNOGENICITY-REDUCED ANTI- :
CR1 ANTIBODY AND COMPOSITIONS :
AND METHODS OF TREATMENT :
BASED THEREON :

DECISION

Applicants' "Petition for Revival of an International Application for Patent Designating the U.S. Abandoned Unintentionally Under 37 C.F.R. §1.137(b)" filed with the national stage papers on 30 September 2005 is hereby **GRANTED** as follows:

The basic national fee, surcharge fee and petition fee for a small entity have been paid. Applicants' statement is sufficient to meet the requirements of 37 CFR 1.137(b)(3). A terminal disclaimer is not required. Accordingly, all requirements under 37 CFR 1.137(b) have been satisfied.

A signed oath or declaration was not included with any of the papers submitted.

Accordingly, this application is being forwarded to the United States Designated/Elected Office for further processing including mailing a Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US) (Form PCT/DO/EO/905) indicating that an oath or declaration in compliance with 37 CFR 1.497(a) and (b) is required.



James Thomson
Attorney Advisor
Office of PCT Legal Administration

Tel.: (571) 272-3302